Pyelonephritis
Drug research and approvals for pyelonephritis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 19, 2026, 6 studies of pyelonephritis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 6
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 3
- Diagnosis of Abdominal Pain Using RNA Levels: The NATURAL StudyNCT07579312 · Not reported · True Bearing Diagnostics, Inc. · starts Apr 17, 2026
- Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in ChildrenNCT07070102 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Sep 1, 2025
- Clinical Trial Comparing Oral Versus Intravenous Cefuroxime in Pregnant Women with PyelonephritisNCT06527560 · Phase 4 · Hospital de Clinicas de Porto Alegre · starts Sep 9, 2024
- Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a…NCT05597540 · Phase 3 · Assistance Publique - Hôpitaux de Paris · starts Feb 22, 2024
- 3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in ChildrenNCT05544565 · Phase 4 · Assistance Publique - Hôpitaux de Paris · starts Mar 22, 2023
- The Validity of the Quick Renal MRI in Pediatric Kidney DiseaseNCT03959163 · Not applicable · University of Wisconsin, Madison · starts May 7, 2019
Approved 8
- CiprofloxacinBacterial DNA gyrase inhibitor
- DoripenemBacterial penicillin-binding protein inhibitor
- CeftazidimeBacterial penicillin-binding protein inhibitor
- AvibactamBacterial beta-lactamase TEM inhibitor
- CefepimeBacterial penicillin-binding protein inhibitor
- PlazomicinBacterial 70S ribosome inhibitor
- AztreonamBacterial penicillin-binding protein inhibitor
- RelebactamBeta-lactamase SHV-1 inhibitor
Phase 3 12 of 13
- LevofloxacinDNA gyrase inhibitor
- SulfamethoxazoleBacterial dihydropteroate synthase inhibitor
- TrimethoprimBacterial dihydrofolate reductase inhibitor
- CilastatinRenal dipeptidase inhibitor
- TazobactamBacterial beta-lactamase TEM inhibitor
- MeropenemBacterial penicillin-binding protein inhibitor
- ImipenemBacterial penicillin-binding protein inhibitor
- CeftolozaneBacterial penicillin-binding protein inhibitor
- Clavulanic acidBacterial beta-lactamase TEM inhibitor
- CeftibutenBacterial penicillin-binding protein inhibitor
- AmoxicillinBacterial penicillin-binding protein inhibitor
- Omega-3-ACID ethyl esters
Phase 2 4
- CycloserineD-alanylalanine synthetase inhibitor
- ErtapenemBacterial penicillin-binding protein inhibitor
- AcetylcysteineGlutathione precursor
- Benapenem
How its trials ended
90 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 37 whose ending is known, 62% met their primary endpoint, 8% missed it and 30% stopped early.
- Completed, result not reported3033%
- Met its primary endpoint2326%
- Ongoing1517%
- Status unknown89%
- Stopped: other or unclear78%
- Missed its primary endpoint33%
- Stopped: lack of efficacy22%
- Stopped: enrollment or feasibility11%
- Stopped: sponsor or business decision11%
| Mar 21, 2024 | ExblifepCefepime; enmetazobactam | Advanz Pharma Limited | EMA ↗ |
| Nov 20, 2018 | VaboremMeropenem; vaborbactam | Menarini International Operations Luxembourg S.A. | EMA ↗ |
| Sep 18, 2015 | ZerbaxaCeftolozane; tazobactam | Merck Sharp & Dohme B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA